High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience: Br J Haematol

E. Olavarria, E. Kanfer, R. Szydlo, S. O'Brien, C. Craddock, J. Apperley, J. Goldman

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)
Original languageEnglish
Pages (from-to)769-777
Number of pages9
JournalBritish Journal of Haematology
Issue number4
Publication statusPublished - 2000


  • cml stem cell transplantation busulphan conditioning regimens toxicity bone-marrow transplantation chronic myelogenous leukemia donor leukocyte transfusions regimen-related toxicity versus-host disease chronic phase busulfan pharmacokinetics relapse therapy cml

Cite this